Free Trial

Pacira BioSciences (PCRX) Competitors

Pacira BioSciences logo
$21.59 -0.70 (-3.14%)
Closing price 04:00 PM Eastern
Extended Trading
$21.58 0.00 (-0.02%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PCRX vs. PRGO, SUPN, NKTR, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRK

Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry.

Pacira BioSciences vs. Its Competitors

Pacira BioSciences (NASDAQ:PCRX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Pacira BioSciences has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$700.97M1.43-$99.56M-$2.28-9.47
Perrigo$4.37B0.85-$171.80M-$1.31-20.57

In the previous week, Perrigo had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 5 mentions for Perrigo and 3 mentions for Pacira BioSciences. Perrigo's average media sentiment score of 1.14 beat Pacira BioSciences' score of 0.66 indicating that Perrigo is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacira BioSciences
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Perrigo
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 0.7% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pacira BioSciences currently has a consensus price target of $26.44, indicating a potential upside of 22.48%. Perrigo has a consensus price target of $33.00, indicating a potential upside of 22.45%. Given Pacira BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
Perrigo
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

Pacira BioSciences has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Perrigo has a net margin of -4.16% compared to Pacira BioSciences' net margin of -14.78%. Pacira BioSciences' return on equity of 13.78% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Pacira BioSciences-14.78% 13.78% 7.00%
Perrigo -4.16%8.93%3.87%

Summary

Pacira BioSciences beats Perrigo on 11 of the 16 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCRX vs. The Competition

MetricPacira BioSciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.03B$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-9.478.2821.0120.09
Price / Sales1.43303.17433.8199.01
Price / Cash5.1642.5936.1658.27
Price / Book1.287.678.125.65
Net Income-$99.56M-$55.28M$3.25B$257.91M
7 Day Performance-5.72%2.50%0.97%2.09%
1 Month Performance-10.60%11.70%7.36%11.13%
1 Year Performance6.78%4.89%31.31%18.40%

Pacira BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCRX
Pacira BioSciences
3.1024 of 5 stars
$21.59
-3.1%
$26.44
+22.5%
+6.2%$1.03B$700.97M-9.47720
PRGO
Perrigo
4.6253 of 5 stars
$26.74
-1.7%
$33.00
+23.4%
-2.0%$3.74B$4.37B-20.418,379News Coverage
Positive News
SUPN
Supernus Pharmaceuticals
2.3694 of 5 stars
$31.45
-1.7%
$36.00
+14.5%
+16.0%$1.79B$661.82M28.33580Positive News
NKTR
Nektar Therapeutics
4.0678 of 5 stars
$23.47
-5.2%
$84.17
+258.6%
+22.6%$307.20M$98.43M-2.45220Analyst Revision
High Trading Volume
OMER
Omeros
3.7837 of 5 stars
$3.08
-3.8%
$18.00
+484.4%
-33.1%$187.50MN/A-1.16210Positive News
Analyst Revision
Gap Up
ASMB
Assembly Biosciences
3.7919 of 5 stars
$18.56
+2.3%
$33.00
+77.8%
+27.1%$138.54M$28.52M-2.98100Trending News
CPIX
Cumberland Pharmaceuticals
0.8866 of 5 stars
$3.04
-3.5%
N/A+152.4%$47.13M$37.87M-12.1680Trending News
LLY
Eli Lilly and Company
4.979 of 5 stars
$772.82
-1.0%
$1,011.61
+30.9%
-15.8%$739.87B$45.04B62.8847,000Trending News
JNJ
Johnson & Johnson
4.7823 of 5 stars
$155.23
-0.5%
$170.88
+10.1%
+4.1%$375.37B$88.82B17.27138,100Trending News
Earnings Report
Dividend Announcement
Analyst Forecast
Options Volume
Analyst Revision
ABBV
AbbVie
4.7838 of 5 stars
$187.44
-1.0%
$211.29
+12.7%
+9.1%$334.34B$56.33B79.7655,000Trending News
Ex-Dividend
Analyst Revision
MRK
Merck & Co., Inc.
4.9955 of 5 stars
$80.89
0.0%
$109.19
+35.0%
-35.2%$203.22B$64.17B11.7775,000Positive News

Related Companies and Tools


This page (NASDAQ:PCRX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners